ClinicalTrials.gg
CompletedNCT04515641Updated Jul 17, 2025Results posted

Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)

A Phase 1 interventional study of Islatravir in Human Immunodeficiency Virus (HIV) Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-17.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, single-dose study of the plasma pharmacokinetics (PK), safety, and tolerability of islatravir (ISL, MK-8591), and the intracellular PK of ISL triphosphate (ISL-TP) in male and female adult participants with moderate hepatic impairment and in healthy matched control participants.

02

Conditions studied

  • Human Immunodeficiency Virus (HIV) Infection

Browse trials for

03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.

This study's enrollment of 12 is below the median of 96 across 2,252 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Control Participants:

  • Is in good health based on medical history, physical examination, vital sign (VS) measurements and (ECGs) performed prior to randomization
  • Is in good health based on laboratory safety tests obtained at the screening visit and prior to administration of the initial dose of study drug.
  • Has a (BMI) ≥18.5 and ≤40 kg/m2

Hepatic Impairment Participants:

  • Has a diagnosis of chronic (> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency with features of cirrhosis due to any etiology
  • Has a score on the scale ranging from 7 to 9 (moderate hepatic insufficiency) at screening
  • With the exception of hepatic impairment, is in generally good health
  • Has a BMI ≥ 18.5 and ≤ 40 kg/m2

Healthy and Hepatic Impairment Participants:

  • Males : uses according to local regulations
  • Females: is not pregnant or breastfeeding and one of the following applies:
  • Is not a woman of (WOCBP) OR
  • Is a WOCBP and uses an acceptable contraceptive method
  • A WOCBP with negative highly sensitive pregnancy test within 24 hours of study intervention

Exclusion criteria

Exclusion Criteria:

  • Has a history of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Is mentally or legally incapacitated, has significant emotional problems at the time of prestudy (screening) visit or expected during the conduct of the study or has a history of clinically significant psychiatric disorder of the last 5 years
  • Has a history of cancer ()
  • Has a history of significant multiple and/or severe allergies, or has had an anaphylactic reaction or significant intolerability (ie, systemic allergic reaction) to prescription or non-prescription drugs or food
  • Has known to the active substance or any of the of the study drug
  • Is positive for surface antigen, antibodies, -1 or HIV-2
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit
  • Is unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies beginning approximately 2 weeks (or 5 half-lives) prior to study drug administration, throughout the study, until the poststudy visit
  • Has participated in another study within 4 weeks (or 5 half-lives, whichever is greater) prior to the prestudy (screening) visit
  • Has a >470 for males or >480 ms for females, has a history of risk factors for Torsades de Pointes (eg, heart failure/cardiomyopathy or family history of long QT syndrome), has uncorrected hypokalemia or hypomagnesemia, is taking concomitant medications that prolong the QT/QTc interval
  • Is not considered low risk of having HIV infection
  • Is a smoker or user of electronic cigarettes and/or has used nicotine or nicotine-containing products (eg, nicotine patch) within 3 months of screening
  • Consumes greater than 3 glasses of alcoholic beverages per day
  • Consumes more than 6 caffeinated beverages per day
  • Is a regular user of illicit drugs or has a history of drug abuse within 2 years
  • Presents any concern to the investigator regarding safe study participation
  • Is unwilling to comply with study restrictions
  • Is or has an immediate family member who is investigational site or Sponsor staff directly involved with this study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Moderate Hepatic Impairment

    Participants receive a single dose of ISL 60 mg.

    Drug: Islatravir

  • Experimental
    Healthy Controls

    Participants receive a single dose of ISL 60 mg.

    Drug: Islatravir

Interventions

  • Two ISL 30 mg capsules taken by mouth.

    Also known as: MK-8591

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Islatravir (ISL) in Plasma

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose

  2. Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of ISL in Plasma

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose

  3. Maximum Concentration (Cmax) of ISL in Plasma

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose

  4. Time to Maximum Concentration (Tmax) of ISL in Plasma

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Tmax of plasma ISL was expressed as a median.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose

  5. Apparent Terminal Half-Life (t½) of ISL in Plasma

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose

  6. Apparent Total Clearance (CL/F) of ISL in Plasma

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose

  7. Apparent Volume of Distribution During Terminal Phase (Vz/F) of ISL in Plasma

    Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.

    Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose

Secondary outcomes

  1. Percentage of Participants With an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to 28 days

  2. Percentage of Participants Who Discontinued From the Study Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

    Time frame: Up to 28 days

  3. AUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC)

    Participants were treated with ISL, and peripheral blood samples were collected from pre-dose up to 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours post-dose

  4. AUC0-last of ISL-TP in PBMC

    Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours post-dose

  5. Cmax of ISL-TP in PBMC

    Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours post-dose

  6. Concentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC

    Participants were treated with ISL and peripheral blood samples were collected at 24 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: 24 hours post-dose

  7. Concentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC

    Participants were treated with ISL and peripheral blood samples were collected at 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: 168 hours post-dose

  8. Concentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC

    Participants were treated with ISL and peripheral blood samples were collected at 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

    Time frame: 672 hours post-dose

  9. Tmax of ISL-TP in PBMC

    Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The Tmax of ISL-TP was expressed as a median.

    Time frame: Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours post-dose

  10. T1/2 of ISL-TP in PBMC

    Participants were treated with ISL, and peripheral blood samples were collected from pre-dose to 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.

    Time frame: Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours post-dose

07

Results

Posted Jul 3, 2023

Participant flow

Male and females with moderate hepatic impairment between the ages of 18 and 75 years old (inclusive), and healthy matched controls were enrolled in this study

Participant flow — Overall Study
MilestoneParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Started66
Completed66
Not completed00

Outcome measures

PrimaryArea Under the Curve From Time 0 to Infinity (AUC0-inf) of Islatravir (ISL) in Plasma

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose
Reported as:
Geometric mean · Hours*μmol/Liter
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Islatravir (ISL) in Plasma
Hours*μmol/LiterParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Islatravir (ISL) in Plasma5.81 (5.08 to 6.64)7.74 (5.67 to 10.6)
Statistical analysis
  • Participants With Moderate Hepatic Impairment vs Healthy Matched Control Participants · Gmr: 0.75 · 90% CI 0.58 to 0.96Participants with Moderate Hepatic Impairment / Healthy Matched Control Participants
PrimaryArea Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of ISL in Plasma

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose
Reported as:
Geometric mean · Hours*μmol/Liter
Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of ISL in Plasma
Hours*μmol/LiterParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Area Under the Curve From Time 0 to Last Sampling Time (AUC0-last) of ISL in Plasma5.25 (4.55 to 6.07)6.97 (5.04 to 9.63)
Statistical analysis
  • Participants With Moderate Hepatic Impairment vs Healthy Matched Control Participants · Gmr: 0.75 · 90% CI 0.58 to 0.98Participants with Moderate Hepatic Impairment / Healthy Matched Control Participants
PrimaryMaximum Concentration (Cmax) of ISL in Plasma

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose
Reported as:
Geometric mean · μmol/Liter
Maximum Concentration (Cmax) of ISL in Plasma
μmol/LiterParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Maximum Concentration (Cmax) of ISL in Plasma0.834 (0.440 to 1.58)1.28 (0.822 to 1.98)
Statistical analysis
  • Participants With Moderate Hepatic Impairment vs Healthy Matched Control Participants · Gmr: 0.65 · 90% CI 0.38 to 1.14Participants with Moderate Hepatic Impairment / Healthy Matched Control Participants
PrimaryTime to Maximum Concentration (Tmax) of ISL in Plasma

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Tmax of plasma ISL was expressed as a median.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose
Reported as:
Median · Hours
Time to Maximum Concentration (Tmax) of ISL in Plasma
HoursParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Time to Maximum Concentration (Tmax) of ISL in Plasma1.00 (1.00 to 6.00)1.00 (1.00 to 2.00)
PrimaryApparent Terminal Half-Life (t½) of ISL in Plasma

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose
Reported as:
Geometric mean · Hours
Apparent Terminal Half-Life (t½) of ISL in Plasma
HoursParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Apparent Terminal Half-Life (t½) of ISL in Plasma72.9 ± 13.683.9 ± 12.0
PrimaryApparent Total Clearance (CL/F) of ISL in Plasma

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose
Reported as:
Geometric mean · Liters/Hour
Apparent Total Clearance (CL/F) of ISL in Plasma
Liters/HourParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Apparent Total Clearance (CL/F) of ISL in Plasma35.1 ± 12.926.5 ± 30.3
PrimaryApparent Volume of Distribution During Terminal Phase (Vz/F) of ISL in Plasma

Participants were treated with ISL, and blood samples were collected from pre-dose up to 168 hours post-dose to determine the concentration of plasma ISL. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.

Time frame:
Pre-dose and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, and 168 hours post-dose
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution During Terminal Phase (Vz/F) of ISL in Plasma
LitersParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Apparent Volume of Distribution During Terminal Phase (Vz/F) of ISL in Plasma3714 ± 18.43197 ± 38.6
SecondaryPercentage of Participants With an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to 28 days
Reported as:
Number · Percentage of participants
Percentage of Participants With an Adverse Event (AE)
Percentage of participantsParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Percentage of Participants With an Adverse Event (AE)16.716.7
SecondaryPercentage of Participants Who Discontinued From the Study Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.

Time frame:
Up to 28 days
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued From the Study Due to an AE
Percentage of participantsParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Percentage of Participants Who Discontinued From the Study Due to an AE0.00.0
SecondaryAUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC)

Participants were treated with ISL, and peripheral blood samples were collected from pre-dose up to 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours post-dose
Reported as:
Geometric mean · hours*μmol/Liter
AUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC)
hours*μmol/LiterParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
AUC0-inf of ISL Triphosphate (ISL-TP) in Peripheral Blood Mononuclear Cells (PBMC)19500 (15200 to 25000)25700 (19000 to 34700)
Statistical analysis
  • Participants With Moderate Hepatic Impairment vs Healthy Matched Control Participants · Gmr: 0.76 · 90% CI 0.57 to 1.00Participants with Moderate Hepatic Impairment / Healthy Matched Control Participants
SecondaryAUC0-last of ISL-TP in PBMC

Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours post-dose
Reported as:
Geometric mean · hours*μmol/Liter
AUC0-last of ISL-TP in PBMC
hours*μmol/LiterParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
AUC0-last of ISL-TP in PBMC18600 (14700 to 23500)24100 (17300 to 33600)
Statistical analysis
  • Participants With Moderate Hepatic Impairment vs Healthy Matched Control Participants · Gmr: 0.77 · 90% CI 0.58 to 1.03Participants with Moderate Hepatic Impairment / Healthy Matched Control Participants
SecondaryCmax of ISL-TP in PBMC

Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours post-dose
Reported as:
Geometric mean · μmol/Liter
Cmax of ISL-TP in PBMC
μmol/LiterParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Cmax of ISL-TP in PBMC109 (83.7 to 141)113 (68.0 to 189)
Statistical analysis
  • Participants With Moderate Hepatic Impairment vs Healthy Matched Control Participants · Gmr: 0.96 · 90% CI 0.63 to 1.46Participants with Moderate Hepatic Impairment / Healthy Matched Control Participants
SecondaryConcentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC

Participants were treated with ISL and peripheral blood samples were collected at 24 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
24 hours post-dose
Reported as:
Geometric mean · μmol/Liter
Concentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC
μmol/LiterParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Concentration at 24 Hours Post Dose (C24) of ISL-TP in PBMC103 (74.7 to 141)97.6 (54.3 to 175)
Statistical analysis
  • Participants With Moderate Hepatic Impairment vs Healthy Matched Control Participants · Gmr: 1.05 · 90% CI 0.65 to 1.71Participants with Moderate Hepatic Impairment / Healthy Matched Control Participants
SecondaryConcentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC

Participants were treated with ISL and peripheral blood samples were collected at 168 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
168 hours post-dose
Reported as:
Geometric mean · μmol/Liter
Concentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC
μmol/LiterParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Concentration at 168 Hours Post Dose (C168) of ISL-TP in PBMC39.9 (30.0 to 53.1)46.4 (29.6 to 72.6)
Statistical analysis
  • Participants With Moderate Hepatic Impairment vs Healthy Matched Control Participants · Gmr: 0.86 · 90% CI 0.59 to 1.26Participants with Moderate Hepatic Impairment / Healthy Matched Control Participants
SecondaryConcentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC

Participants were treated with ISL and peripheral blood samples were collected at 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The 95% confidence interval was derived from a fixed effects model performed on natural log-transformed values.

Time frame:
672 hours post-dose
Reported as:
Geometric mean · μmol/Liter
Concentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC
μmol/LiterParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Concentration at 672 Hours Post Dose (C672) of ISL-TP in PBMC3.80 (2.25 to 6.42)5.82 (4.38 to 7.74)
Statistical analysis
  • Participants With Moderate Hepatic Impairment vs Healthy Matched Control Participants · Gmr: 0.65 · 90% CI 0.42 to 1.01Participants with Moderate Hepatic Impairment / Healthy Matched Control Participants
SecondaryTmax of ISL-TP in PBMC

Participants were treated with ISL and peripheral blood samples were collected from pre-dose up to 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The Tmax of ISL-TP was expressed as a median.

Time frame:
Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours post-dose
Reported as:
Median · Hours
Tmax of ISL-TP in PBMC
HoursParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
Tmax of ISL-TP in PBMC24.00 (4.00 to 48.00)48.00 (24.00 to 96.00)
SecondaryT1/2 of ISL-TP in PBMC

Participants were treated with ISL, and peripheral blood samples were collected from pre-dose to 672 hours post-dose to determine the concentration of ISL-TP in PBMCs. The Geometric Coefficient of Variation was expressed as a percent (%CV), and is calculated from the square root of corresponding estimated variance obtained for each population in fixed effect model multiplied by 100.

Time frame:
Predose and 4, 24, 48, 96, 168, 240, 336, 408, 504, and 672 hours post-dose
Reported as:
Geometric mean · Hours
T1/2 of ISL-TP in PBMC
HoursParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
T1/2 of ISL-TP in PBMC148 ± 18.4169 ± 31.9

Adverse events

Collected over Up to 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants With Moderate Hepatic Impairment0/6 (0%)0/6 (0%)1/6 (16.7%)
Healthy Matched Control Participants0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
EventParticipants With Moderate Hepatic ImpairmentHealthy Matched Control Participants
HeadacheNervous system disorders1/61/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Participants With Moderate Hepatic ImpairmentHealthy Matched Control ParticipantsTotal
Mean60.5 ± 9.459.5 ± 6.660.0 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Participants With Moderate Hepatic ImpairmentHealthy Matched Control ParticipantsTotal
Female437
Male235
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Participants With Moderate Hepatic ImpairmentHealthy Matched Control ParticipantsTotal
Hispanic or Latino459
Not Hispanic or Latino213
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Participants With Moderate Hepatic ImpairmentHealthy Matched Control ParticipantsTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White6511
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Clinical Pharmacology of Miami ( Site 0001)
    Miami, Florida 33014, United States
09

References and documents

Publications

  • Matthews RP, Patel M, Liu W, Liu Y, Rondon JC, Vargo RC, Stoch SA, Iwamoto M. Pharmacokinetics of islatravir in participants with moderate hepatic impairment. Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0155324. doi: 10.1128/aac.01553-24. Epub 2025 Mar 5. PubMed 40042304 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Sep 2021, 10 months.

Results were first posted in Jul 2023, 1 year 9 months after primary completion.

Of 76 industry-sponsored phase 1 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 10 months is above that.

Counting every sponsor, half of 139 studies reached it within 14 months; a quarter within 4 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2020
First posted
Aug 17, 2020
StartActual
Nov 5, 2020
Primary completionActual
Sep 13, 2021
CompletionActual
Sep 13, 2021
Results first posted
Jul 3, 2023
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04515641
Responsible party
Sponsor
First posted
Aug 17, 2020
Start date
Nov 5, 2020
Primary completion
Sep 13, 2021
Completion
Sep 13, 2021
Results posted
Jul 3, 2023
Last update
Jul 17, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Islatravir

Start the discussion